Work

Buprenorphine alone and in combination with naloxone in non-dependent humans

Year: 1992

Type: article

Abstract: This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonist-antagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.

Source: Drug and Alcohol Dependence

DOI: 10.1016/0376-8716(92)90061-g

Authors: Linda L. Weinhold, Kenzie L. Preston, Magi Farre, Ira A. Liebson, George E. Bigelow

Institutions: Johns Hopkins University, Johns Hopkins Medicine

Language: English

Topic: Opioid Use Disorder Treatment

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,380